



NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION, DISTRIBUTION OR DISSEMINATION DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES

BioNxt Solutions Announces Extension of Warrants

Vancouver, British Columbia, Canada (July 12, 2024) - BioNxt Solutions Inc. (“**BioNxt**” or the “**Company**”) (CSE: BNXT / OTC: XPHYF / FSE: 4XT) announces that it intends to extend the expiry date of 1,873,000 common share purchase warrants (the “**Warrants**”), as follows:

- the expiry date of 72,500 Warrants issued on July 29, 2022, and originally set to expire on July 29, 2024, will be extended to July 29, 2025;
- the expiry date of 1,112,500 Warrants issued on August 29, 2022, and originally set to expire on August 29, 2024, will be extended to August 29, 2025; and
- the expiry date of 688,000 Warrants issued on August 30, 2022, and originally set to expire on August 30, 2024, will be extended to August 30, 2025.

Each Warrant entitles the holder thereof to acquire one common share in the capital of the Company (a “**Share**”) at a price of \$0.50 per Share. None of the 1,873,000 Warrants outstanding are held by insiders of the Company. All other terms of the Warrants, including the exercise price, will remain unchanged.

About BioNxt Solutions Inc.

BioNxt Solutions Inc. is a bioscience accelerator focused on next-generation drug formulations and delivery systems, diagnostic screening tests, and new active pharmaceutical production and evaluation, including: precision transdermal and oral dissolvable drug formulations; rapid, low-cost infectious disease and oral health screening tests; and standardization and clinical evaluation of emerging active pharmaceutical ingredients for neurological applications. The Company has research and development operations in North America and Europe, with an operational focus in Germany, and is currently focused on regulatory approval and commercialization of medical products for European markets.

For more Company information, please visit <https://bionxt.com/> or review its profiles on www.sedarplus.ca and on the Canadian Securities Exchange’s website, www.thecse.com.

BioNxt Solutions Inc.

Wolfgang Probst, Interim CEO

Email: info@bionxt.com

Phone: +1 780-818-6422

The securities of the Company referred to in this news release have not been and will not be registered under the United States Securities Act of 1933, as amended (the “**U.S. Securities Act**”), or any state securities laws. Accordingly, the securities of the Company may not be offered or sold within the United States unless registered under the U.S. Securities Act and applicable state securities laws or pursuant to an exemption from the registration requirements of the U.S. Securities Act and applicable state securities



laws. This news release does not constitute an offer to sell or a solicitation of any offer to buy any securities of the Company in any jurisdiction in which such offer, solicitation or sale would be unlawful.

Forward-Looking Information

The Canadian Securities Exchange has neither approved nor disapproved the contents of this news release.

This news release includes certain statements that may be deemed “forward-looking statements”. All statements in this new release, other than statements of historical facts, that address events or developments that the Company expects to occur, are forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words “expects”, “plans”, “anticipates”, “believes”, “intends”, “estimates”, “projects”, “potential” and similar expressions, or that events or conditions “will”, “would”, “may”, “could” or “should” occur. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in the forward-looking statements. Factors that could cause the actual results to differ materially from those in forward-looking statements include market prices, continued availability of capital and financing, and general economic, market or business conditions. Investors are cautioned that any such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking statements. Forward-looking statements are based on the beliefs, estimates and opinions of the Company’s management on the date the statements are made. Except as required by applicable securities laws, the Company undertakes no obligation to update these forward-looking statements in the event that management’s beliefs, estimates or opinions, or other factors, should change.